Pfizer gets clearance for vaccine for children aged 5 to 11

Washington: In what is good news for the world waiting for children’s vaccine, America has taken an important step to vaccinate millions of children. The Food and Drug Administration (FDA) has approved Pfizer’s vaccine for emergency use for children aged 5-11. With this, Pfizer has become the first vaccine to receive FDA approval in the US.

Pfizer and BioNTech reported that two doses of the vaccine would be given to children over a 21-day span. Since the beginning of this epidemic, more than 6 million children in America were infected with corona. Every week a large number of youth were infected. Albert Borla, president and chief executive officer of Pfizer, said: “Our efforts continue to help protect and control families and communities. In this we have achieved another success.

With this, the US has joined the list of countries, including China, Chile, Cuba and the United Arab Emirates, which are vaccinating young children. A high-level medical panel took this decision while supporting vaccination for children. While making this decision, the panel took into account that the benefits of the Pfizer COVID vaccine outweigh the risks of side-effects.

नोट: अगर आपको यह खबर पसंद आई तो इसे शेयर करना न भूलें, देश-विदेश से जुड़ी ताजा अपडेट पाने के लिए कृपया The Lucknow Tribune के  Facebook  पेज को Like व Twitter पर Follow करना न भूलें... ------------------------- ------------------------------------------------------ -------------------------------------------------------- ------------------------------------------------------------------- --------------------------------------------- --------------------------------------------------------------- --------------------------------------------------------- --------------------------------------------------------------------------   ----------------------------------------------------------- -------------------------------------------------- -----------------------------------------------------------------------------------------
----------- -------------------------------------------------------------------------------------------------------------------------------------------------
E-Paper